Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 349-352

  Nasti, Tahseen H ^a   Khan, Masood A ^a,b   Owais, M ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Drug delivery pH sensitive liposomes; Lysosomes

Indexed keywords

LIPOSOME; NYSTATIN; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SENSITIVITY; LIVER; MALE; MOUSE; NONHUMAN; PH; SURVIVAL;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BRAIN; CRYPTOCOCCOSIS; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; INTERCALATING AGENTS; LIPOSOMES; LIVER; MALE; MICE; MICE, INBRED BALB C; NYSTATIN; PHOSPHATIDYLCHOLINES; SURVIVAL ANALYSIS;

EID: 31544467343     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki454     Document Type: Article

References (14)

1. Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991; 13: 480-6.
2. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14: S43-51.
3. Rude TH, Toffaletti DL, Cox GM et al. Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect Immun 2002; 70: 5684-94.
4. Chretien F, Lortholary O, Kansau I et al. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 2002; 186: 522-30.
5. Denning DW. Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 1996; 12: 1147-201.
6. Dupont B. Overview of lipid formulations of amphotericin B. J Antimicrob Chemother 2002; 49 Suppl 1: 31-6.
7. Straubinger RM. pH-sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells. Methods Enzymol 1993; 221: 361-76.
8. Hope MJ, Mui B, Ansell S et al. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid based drugs. Mol Membr Biol 1998; 15: 1-14.
9. Singleton WS, Gray MS, Brown ML. A method for adsorbent fractionation of cottonseed oil for experimental intravenous fat emulsions. J Am Oil Chem Soc 1965; 42: 53-6.
10. Owais M, Gupta CM. Liposome mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000; 267: 3946-56.
11. Mehta TR, Hopfer RL, McQueen T et al. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987; 31: 1901-3.
12. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Villanova, PA, USA, 1997.
13. Khan MA, Syed FM, Nasti HT et al. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. J Drug Target 2003; 11: 93-9.
14. Lutwyche P, Cordeiro C, Wiseman DJ et al. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 1998; 42: 2511-20.